Board summary
Key figures
40,473
Registered population
61.5% aged 18–64
18.7%
Aged 65+
ICB 21.9% · England 17.9%
13.3%
Ethnic minority (non-White)
3.9% Asian · England 9.6%
13.5%
In IMD quintile 1
ICB 9.2% · England 21.0%
~5,466
Core20 residents (est.)
Resident basis; registered basis ~6,152 · see page 3
6,063
Hypertension register
+8.46% in 3 yrs · England +5.60%
434
SMI register
9.4% of Brighton and Hove (LAD)'s
989
COPD register
Reviews +5.05% in 3 yrs
Forecast to 2030
7,033
Hypertension patients, 2030
+970 on today
66.8%
QRISK ≥20% on statins, 2030
+1.82pp over 3 yrs
4.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Cardiovascular treatment thresholds trail England.
Under-80s blood pressure control is 65.0% (England 67.8%) and QRISK ≥ 20% lipid therapy is 63.0% (England 63.6%), which may reflect titration lags.
Wide inter-practice immunisation and access variation.
QOF vaccination achievement spans 42.2 pp from 38.9% at Mile Oak Medical Centre to 81.0% at Portslade Health Centre, alongside a 35.1 pp phone-access.
Physical health checks in SMI outpace benchmarks.
Blood pressure recording on the mental health register rose +10.7 pp over 2023 to 2025 (England +4.4 pp), reaching 86.5% against 83.4% nationally.
Population, age and ethnicity
Aged 65+ at 18.7% and children at 19.7% exceed borough rates in West Hove
West Hove PCN serves 40,473 registered patients. Children aged 0-17 comprise 19.7% (7,988 patients), above Brighton and Hove (LAD) (15.0%) and NHS Sussex Integrated Care Board (17.7%), and in line with England (19.6%). Patients aged 65+ make up 18.7% (7,586 patients), above the LAD (14.0%), below the ICB (21.9%) and above England (17.9%). Usual residents are 86.7% White (LAD 85.4%, ICB 91.0%, England 81.1%), leaving a 13.3% ethnic minority share. Practice list sums (45,197) and registered 0-17 sums (8,767) exceed PCN totals.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Brighton and Hove (LAD) local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Brighton and Hove LA) | 2,702 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 78.6% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 57.8% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Brighton and Hove LA) | 1,485 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Brighton and Hove LA) | 19.9 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
West Hove PCN has 13.5% Core20 patients, distributed unevenly by concentration and volume
West Hove PCN has an average IMD decile of 5.5 and 13.5% of registered patients in the Core20 cohort, below England (21.0%) and Brighton and Hove (LAD) (17.6%) but above NHS Sussex Integrated Care Board (9.2%). Weighted practice share is 13.61% versus the 13.49% PCN figure (a 0.12 percentage point difference). Mile Oak Medical Centre has the highest Core20 concentration at 15.28% (1,333 estimated patients), while Wish Park Surgery holds the largest volume at 1,503 estimated patients (12.98% share). Deprivation outreach requires balancing high-concentration targeting with high-volume clinical case management.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
434
SMI register
1.04% recorded prevalence
271
Learning disability register
0.65% recorded prevalence
30
Care homes, 823 beds
In the PCN catchment
8.2%
Provide unpaid care
Brighton and Hove (LAD), Census 2021
Learning disability prevalence is 0.7% (271 patients; LAD 0.6%, ICB 0.6%, England 0.6%) and severe mental illness is 1.0% (434 patients; LAD 1.4%, ICB 1.1%, England 1.0%). The catchment includes 30 care homes with 823 beds, though resident registrations are unconfirmed.
Severe mental illness: physical health checks
Recorded SMI prevalence is 1.0% (434 patients; England 1.0%). Across the PCN, 86.5% of SMI patients received a blood pressure check (England 83.4%). Practice recording rates vary: Hove Medical Centre achieved 79.0% and Links Road Surgery reached 73.0%.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,063
Hypertension register
+8.46%
Register growth, 3 yrs
Brighton and Hove (LAD) +7.27% · England +5.60%
+1.17pp
BP control, under 80
≤140/90 · +4.69pp aged 80+
+970
More patients by 2030
Forecast 7,033 (17.06%)
Hypertension case-finding and control
The PCN hypertension register includes 6,063 patients, giving a recorded prevalence of 14.5% against 10.5% in Brighton and Hove (LAD), 16.3% in NHS Sussex Integrated Care Board and 15.2% in England. The register grew +8.5% over 2023 to 2025 (England +5.6%). While 89.8% of patients have a recent blood pressure check (England 90.0%), blood pressure control in patients aged under 80 is 65.0%, below England (67.8%) and the ICB (66.8%), with three-year improvement at +1.8% trailing England (+3.2%). Overall blood pressure treated to target stands at 67.6% (England 70.3%). Current snapshot observation periods were not captured. With blood pressure control in under-80s lagging national benchmarks despite register growth, treatment titration and recall remain key priorities.
Lipids and statins
For patients with QRISK ≥ 20%, lipid-lowering therapy uptake is 63.0%, trailing England (63.6%) though above Brighton and Hove (LAD) (58.9%). Three-year uptake rose +3.0% over 2023 to 2025 (England +6.2%). In CKD, lipid therapy reaches 70.9% (England 70.3%). Reviewing high-risk primary prevention patients lacking lipid therapy could help close the gap against England.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 64,381 | £2.60 | £2.42 | £1.86 | £167,391 |
| Cardiovascular (all), 2025 | 85,732 | £2.91 | £3.32 | £3.33 | £249,480 |
In 2026, the PCN prescribed 64,381 lipid-regulating drug items at £2.60 per item, above Brighton and Hove (LAD) (£2.47), NHS Sussex Integrated Care Board (£2.42) and England (£1.86). Across these items, the PCN spent £47,642 more than at England's unit cost and £11,589 more than at the ICB's unit cost. Prescribing choices can be reviewed against ICB formulary guidance.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+10.91%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.49%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.4% (989 patients), exceeding England (1.9%), Brighton and Hove (LAD) (1.6%) and NHS Sussex Integrated Care Board (2.0%), after growing +17.8% over 2023 to 2025 (England +2.6%). Current COPD reviews stand at 76.2% (England 76.4%). Asthma prevalence is 7.3% (2,891 patients; England 6.6%). While 12-month asthma reviews rose +10.9% over 2023 to 2025 to 66.2% (England +4.4%, reaching 65.7%), an estimated 976 patients (about 980) lack a recorded annual review. Prioritising structured asthma reviews would address this unreviewed cohort.
Cancer register and children's immunisation
Cancer prevalence is 3.6% (1,522 patients; England 3.8%), rising +16.0% over 2023 to 2025 (England +9.0%). In Q1 2025/26, age-5 MMR dose 1 coverage was 96.9% (England 91.7%), while dose 2 was 91.7% (England 82.8%), reflecting a 5.2 pp dose difference. At 24 months, dose 1 coverage was 88.5% (England 88.3%). Pre-school recall could help reduce the dose drop-off before school entry.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
In 2022 across NHS Sussex ICB, 58.5% of staged cancers (4,799 of 8,209) were diagnosed at stage 1 or 2 (England 55.3%), 16.5 pp below the 75.0% national ambition by 2028 (requiring about 1,360 additional early-stage diagnoses annually). Known staging was 64.3% (8,209 of 12,766 registered cancers; England 67.0%). In West Hove PCN, cervical screening coverage in women aged 25 to 49 is 71.2% (England 66.8%), falling 3.1% over 2023 to 2025 (England -1.0%). Across captured practices, coverage is 67.2% at Links Road Surgery, 67.7% at Portslade Health Centre, and 68.3% at Hove Medical Centre. ICB staging describes the wider system rather than PCN performance; declining local screening may delay.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), University Hospitals Sussex NHS Foundation Trust met the 62-day cancer referral to treatment standard for 65.2% of pathways (414 of 635), below East Sussex Healthcare NHS Trust (67.0%), Surrey and Sussex Healthcare NHS Trust (70.0%), NHS Surrey and Sussex Integrated Care Board (71.5%), England (71.2%), and the 85.0% standard. The trust achieved 74.0% on the 28-day faster diagnosis standard (ICB 79.3%; 75.0% standard). In diagnostics, 6-week waits were 5.6% for MRI, 8.6% for CT, and 57.0% for audiology assessments (England 41.5%). These acute trust and diagnostic waiting times describe provider activity rather than PCN performance.
| Pathways within standard (%) | Sussex | East Sussex Healthcare | Surrey and Sussex Healthcare | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.01 | 84.20 | 77.74 | 79.29 | 79.32 |
| 31-day treatment (96%) | 76.79 | 98.19 | 96.20 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 65.20 | 67.04 | 69.97 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Sussex | East Sussex Healthcare | Surrey and Sussex Healthcare | England |
|---|---|---|---|---|
| MRI | 5.62 | 6.48 | 27.53 | 21.40 |
| CT | 8.57 | 0.48 | 18.49 | 9.92 |
| Echocardiography | 0.39 | 21.94 | 43.78 | 28.48 |
| Colonoscopy | 39.35 | 0.74 | 15.11 | 30.83 |
| Gastroscopy | 20.02 | 0.31 | 21.06 | 29.02 |
| All 15 DM01 tests | 12.95 | 5.27 | 28.50 | 23.14 |
| Community services activity | Brighton and Hove residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 23,615 | 309,615 |
| Referrals | 5,590 | 66,930 |
| Patients with a contact | 7,350 | 85,660 |
Community services (residents of Brighton and Hove), Jun 2026 (provisional). In Jun 2026 (provisional), adults aged 65 and over accounted for 60.7% of all community service contacts among Brighton and Hove residents (14,325 of 23,615 contacts). Provider- and PCN-level community activity was not captured. These resident contacts describe borough-level service demand rather than PCN activity, indicating that older adults represent the majority of local community contacts.
Practice variation and patient experience
Immunisation and overall QOF achievement vary across member practices
In 2025/26, overall QOF achievement ranged from 83.9% at Links Road Surgery to 96.0% at Portslade Health Centre. In vaccination and immunisation, achievement spanned 42.2 pp, ranging from 38.9% at Mile Oak Medical Centre to 81.0% at Portslade Health Centre. Delivery variation suggests network-wide review of immunisation call and recall processes.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Portslade | 92 | 12.4 | 50.3% | 65.1% | 83.4% |
| Hove | 123 | 13.8 | 54.4% | 71.3% | 82.4% |
| Links Road Surgery | 84 | 14.6 | 82.4% | 78.8% | 81.9% |
| Mile Oak | 107 | 15.3 | 47.3% | 64.9% | 76.0% |
| Wish Park Surgery | 113 | 13.0 | 56.9% | 69.9% | 72.6% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Thirteen of 25 measures trail England over three years, led by heart failure reviews
Over 2023 to 2025, 13 of 25 measures trail England's three-year change. The widest relative lags are heart failure reviews, which fell 1.4% (England +8.7%, despite current PCN reach of 80.4% versus England's 78.5%), and dementia QOF prevalence, which fell 2.0% (England +6.0%). Strengths include asthma reviews (+10.9% versus England +4.4%, reaching 66.2%) and severe mental illness blood pressure checks, which rose +10.7 pp to 86.5% (England +4.4 pp). This pattern could reflect proactive screening alongside chronic disease review follow-up lags, which recall audits would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Dementia register
QRISK statin treatment
Alcohol record (psychosis)
Cervical screening
Asthma reviews
BP check (SMI)
BP control, 80+
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Brighton and Hove (LAD) | Asset | PCN | Brighton and Hove (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 30 (823 beds) | n/a | Schools (catchment) | 39 | n/a |
| Children's centres | 5 | 14 | Places of worship | 25 | 113 |
| Libraries | 3 | 13 | Homelessness support (VCS) | 0 | no data |
| Primary schools (LA maintained) | 7 | 35 | Primary academies | 5 | 7 |
| Special schools | n/a | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Pharmacist CVD titration and lipid recall
Under-80s hypertension BP control is 65.0% (England 67.8%, ICB 66.8%) and QRISK ≥ 20% lipid therapy is 63.0% (England 63.6%); patient counts are not captured. For discussion, the PCN could run pharmacist-led titration and statin-initiation clinics for patients already on the hypertension and high-QRISK registers, prioritising high-Core20 practices. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Structured annual asthma review catch-up
Although asthma reviews rose +10.9% to 66.2% (England 65.7%, LAD 60.1%) across 2,891 registered patients (7.3% prevalence), an estimated 976 (about 980) patients lack a 12-month review. For discussion, practices could run a standardised asthma review recall with extended or after-school slots and combined inhaler checks. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Practice-targeted immunisation and access review
QOF vaccination achievement spans 42.2 pp (38.9% at Mile Oak Medical Centre to 81.0% at Portslade Health Centre; England 55.2%), and age-5 MMR drops 5.2 pp from dose 1 (96.9%) to dose 2 (91.7%; England 82.8%). Moderate effort to run.
Evidence base: the share of patients in the most deprived quintile is the Core20 targeting measure used to weight inequalities funding, outreach and prevention capacity, and the gradient every clinical indicator should be read against.
Policy anchor: Core20PLUS5 (Core20 = the most deprived 20% by IMD); 10 Year Health Plan, with widening inequalities the equity test of reform.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Practice list reconciliation (p2) | Registered population · Aged 0-17 | Neighbourhood health framework · Medium Term Planning Framework 2026 | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Target SMI physical checks (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension titration and recall review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR recall catch-up (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Pharmacist CVD titration and lipid recall (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · Structured annual asthma review catch-up (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · Practice-targeted immunisation and access review (p12) | Core20 cohort (IMD quintile 1) · MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | Core20PLUS5 · 10YHP equity test · 10YHP sickness to prevention · 95% target | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
